Iptacopan significantly slowed kidney function decline over 24 months compared with placebo in adults with IgA nephropathy. The complement inhibitor was granted accelerated approved in 2024; continued ...
NEW YORK CITY, NY, UNITED STATES, March 23, 2026 /EINPresswire.com/ -- River of Life A Poetic Journey Invites Readers ...
Patients with age-related macular degeneration (AMD) initially may present with distortions in fine visual perception, and disease may be asymptomatic. As the disease develops over time, vision ...
The 2027 BMW i3 is the newest of the German automaker’s “Neue Klasse” EVs, which feature an electric-first design, powerful ...
AlgorithmicTypography is a Processing library that enables designers, researchers, and artists to explore parametric typography systems. It generates animated grids of typographic characters whose ...
Creating a space that feels truly good to live in isn’t about following trends or filling rooms with expensive pieces. The most successful interiors balance three essentials: comfort, function, and ...
— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — SEATTLE--(BUSINESS WIRE)--Omeros ...
— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — YARTEMLEA is the first and only approved ...
Complement-mediated hemolytic uremic syndrome (CM-HUS), commonly referred to as atypical HUS, is a rare thrombotic microangiopathy caused by uncontrolled activation of the alternative complement ...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of ...
(RTTNews) - Omeros Corporation (OMER) today announced that the FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and ...